FORMULATION AND EVALUATION OF MATRIX TABLETS OF GLIPIZIDE EMPLOYING STARCH ACETATE AND ETHYLENE VINYL ACETATE (EVA)

Niranjan Chaurasia*, M. A. Saleem and Sushil Kumar Sah

ABSTRACT

Increased complications and costs of marketing of innovative drugs focused greater attention to the development of sustained release (SR) or controlled release (CR) drug delivery systems. Delivery systems extended release or controlled release rate can achieve predictable and reproducible, the extended duration of activity for the short time of life - drugs, reduced toxicity, and dose reduction request, the optimized therapy and better patient compliance. It is controlled primarily by the type and the proportion of the polymers used in the preparation. The overall objective of this work was to develop a tablet glipizide oral sustained release (SR) prepared by the method of direct compression, using starch acetate and Ethyl vinyl acetate (EVA). Glipizide hydrochloride (HCl), a biguanide, has a relatively short plasma half-life and low absolute bioavailability. The hydrophilic matrix of EVA alone cannot control the release Glipizide effective for 12 h while when combined with starch acetate, may slow down the release of the drug and, therefore, can be successfully employed for the formulation of matrix tablets SR. All the formulated tablets (F1-F9) have shown in vitro dispersion time of less than 60 seconds, showing that formulated Glipizide tablets were better and effective for the treatment of diabetes than conventional tablet. The drug content of all the nine formulations of Glipizide tablets were found to be within the range of 98.35 - 100.15% which were within the limits of BP specifications.

Keywords: Glipizide, Matrix, Biguanides, Hypoglycemic, Polymers.